Education
About Us
Working with TipRanks
Follow Us
Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.58
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$2.13M
Enterprise ValueC$608.36K
Total Cash (Recent Filing)C$17.46K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Apr 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtHaving no reported debt materially lowers fixed obligations and financial distress risk. Over a multi-month horizon this gives management flexibility to prioritize operating stabilization or raise equity on less dilutive terms, and reduces bankruptcy risk relative to leveraged peers.
Improvement In Annual Net Losses (2022→2024)A multi-year reduction in reported annual losses signals operational cost control or structural expense reductions. If sustained, this trend improves runway and increases the probability the business can reach break-even without continual exponential funding, making future planning and investment more durable.
Equity Rebound In TTM After 2025 DropThe rebound in equity after a sharp decline suggests management or financing actions (capital raises, restructuring) restored balance-sheet capacity. A restored equity buffer improves solvency and ability to absorb shocks over coming months, supporting operational continuity while revenue is developed.
Bears Say
Effectively No RevenueSustained absence of meaningful revenue undermines the core business model: without sales there is no confirmation of market demand, no scalable margin base, and limited ability to convert cost reductions into profitable operations. This structural gap heightens dependency on external funding.
Consistent Negative Operating And Free Cash FlowPersistent negative OCF and FCF indicate material cash burn and limited self-funding capacity. Over 2-6 months this constrains investment, hiring, and R&D, forces financing decisions, and increases dilution or execution risk if the company cannot quickly convert operations to cash-generative.
Persistent Net Losses And Negative ROERepeated net losses and negative ROE show the company is destroying shareholder value rather than creating it. This structural profitability gap impairs ability to build retained earnings, weakens investor confidence in long-term returns, and requires consistent external capital to sustain operations.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.09 and its highest was C$0.58 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$2.13M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Apr 03, 2026 which is in 44 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Jan 14, 2026. The company reported -C$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.022.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---